We have reported that chronic heart failure (HF) patients with increased serum bilirubin coincident with acute decompensation have a poor prognosis, indicating severe congestion and low tissue perfusion. The aim of this study was to analyze the possibility of increased bilirubin coincident with acute decompensation as a parameter which indicates the need for intravenous inotropic agents. We stratified 131 decompensated chronic HF patients with a LVEF ≤ 40% and systolic blood pressure between 90 and 120 mmHg, based on total bilirubin levels on admission. In patients with high bilirubin (T-Bil ≥ 1.2 mg/dL), intravenous inotropics contributed to significantly more abundant diuresis, body weight reduction, and decreases in bilirubin and serum creatinine in the first 5 in-hospital days compared to those without (group A: inotropics +; n = 24 versus group B: -; n = 38: 1726 ± 418 versus 1458 ± 424 mL/day: P < 0.05, -3.1 ± 1.6 versus -2.1 ± 2.2 kg: P < 0.05, -0.74 ± 0.51 versus -0.04 ± 0.60 mg/dL: P < 0.01, -0.29 ± 0.89 versus -0.01 ± 0.24 mg/dL: P < 0.01), in spite of no significant difference in the doses of diuretics between the 2 groups. On the contrary, patients with low bilirubin (T-Bil < 1.2 mg/dL) recovered from decompensation equally irrespective of inotropic administration (group C: inotropics +; n = 15 versus group D: -; n = 54: 1557 ± 329 versus 1507 ± 406 mL/day, -2.9 ± 1.7 versus -2.8 ± 1.5 kg, -0.01 ± 0.25 versus -0.08 ± 0.23 mg/dL, 0.02 ± 0.24 versus 0.47 ± 0.19 mg/dL; NS, respectively). Inotropics were administered after all because of unimproved hemodynamics in 26% of group B patients, compared to 4% of group D patients (P < 0.01). Increased bilirubin coincident with HF decompensation can be a useful marker indicating the need for intravenous inotropic agent administration. (Int Heart J 2007; 48: 195-204) 
THE number of heart failure (HF) patients has been increasing steadily and it is thought to be one of the major public health problems from the point of view of an aging population 1) and the associated health care costs. 2) Although advancements in medical and surgical therapies have been made, it is also true that such advances in treatment have given rise to more patients surviving with severe chronic HF. 3, 4) Intravenous inotropic agents are indicated for acute exacerbation of chronic HF patients demonstrating tissue hypoperfusion, or no response to optimal dosages of diuretics and vasodilators at the time of acute decompensation. 5) It is important for clinicians to detect such patients properly and select appropriate management for each individual. On the other hand, liver dysfunction accompanied by the exacerbation of HF has been reported to be caused by a combination of severe congestion and low tissue perfusion. 6, 7) We have reported that increased serum bilirubin coincident with acute HF decompensation indicates a poor prognosis due to increased central venous pressure (CVP), increased pulmonary artery wedge pressure (PAWP), and decreased cardiac index (CI). 8) The aim of this study was to analyze whether increased bilirubin coincident with acute decompensation could be used as an appropriate parameter which indicates the need for administration of intravenous inotropic agents to chronic HF patients.
METHODS

Study population:
Chronic HF patients admitted to Kitasato University Hospital for HF exacerbation with a left ventricular ejection fraction (LVEF) ≤ 40% together with systolic blood pressure (SBP) between 90 and 120 mmHg upon hospital admission from January 1999 to May 2005 were consecutively recruited into this study. HF exacerbation was judged by at least 2 experienced cardiologists according to the Framingham criteria 9) together with other clinical data that included chest x-rays and echocardiography. Patients with acute coronary syndrome, acute myocarditis, hepatobiliary diseases, chronic renal dysfunction (serum creatinine (Cr) levels > 2.0 mg/dL), an active malignancy, or druginduced liver dysfunction were excluded. The final population consisted of 131 patients. The clinical parameters of each patient were retrospectively analyzed during the first 5 in-hospital days. The investigation conformed with the principles outlined in the Helsinki Declaration. Clinical evaluation of patients: Biochemical laboratory data and transthoracic echocardiography were evaluated on admission (day 1). As clinical parameters, blood pressure (BP), heart rate (HR), body weight (BW), urine volume (UV), and the doses of each diuretic and each intravenous inotropic were measured daily. Serum Cr and total bilirubin (T-Bil) levels were followed-up at least twice on _ Vol 48 No 2 days 3 and 5 after admission. The incidences of arrhythmias were also recorded during the observation period. The cumulative doses of furosemide used during the first 5 in-hospital days were calculated as intravenous dose + oral dose/2. 10) Echocardiography was performed using a ProSound SSD-5000 echocardiograph (ALOKA, USA). M-mode images were obtained in the left parasternal long-axis view for the measurement of each chamber dimension, and LVEF was calculated by a modified Simpson's method using 2-dimensional apical chamber views. Statistical analysis: Continuous variables are presented as the mean ± standard deviation. The data were compared using the chi-square test and Mann-Whitney U-test. For all analyses, a 2-sided P value < 0.05 was considered as statistically significant. The statistical package used was SPSS software (11.0.1J for Windows, SPSS Inc., Chicago, USA).
RESULTS
Patient characteristics:
The mean age of the patients was 63.4 ± 15.1 years. Eighty-eight (67%) of the 131 patients were males. Underlying cardiac disorders included ischemic heart disease (38%), dilated cardiomyopathy (41%), valvular heart disease (16%), and others (5%). The proportion of New York Heart Association functional class on admission was 5: 35: 91 (II : III : IV) .
Patients were stratified into 4 groups using the median value of T-Bil (1.2 mg/dL) upon hospital admission with or without the use of intravenous inotropics from the first in-hospital day: group A: T-Bil ≥ 1.2 mg/dL (high bilirubin), inotropics (+); group B: T-Bil ≥ 1.2 mg/dL, inotropics (-); group C: T-Bil < 1.2 mg/dL (low bilirubin), inotropics (+); and group D: T-Bil < 1.2 mg/dL, inotropics (-). There were no significant differences in the patient characteristics except for BP and the data from echocardiography between groups C and D (Table I) .
In patients with high bilirubin, there was no significant difference in the cumulative dose of furosemide in the first 5 in-hospital days between groups A and B (185.0 ± 84.5 versus 187.5 ± 153.7 mg; NS). In patients with low bilirubin, group C had higher doses of furosemide compared with group D (196.0 ± 97.1 versus 139.1 ± 73.0; P < 0.05). There were also no significant differences in the frequency, dose, or administration period of other diuretics such as carperitide (Table I) , torasemide, azosemide, spironolactone, and trichlormethiazide between groups A and B or C and D (data not shown).
Time course of hemodynamics and adverse effects during administration of inotropics according to bilirubin on admission:
Administration of intravenous inotropics beginning the first in-hospital day was decided upon by the attending physician based on hemodynamic impairment in individual patients in groups A and C.
_ _
Adrenergic agonists were mainly used to treat decompensated patients in groups A and C (Table II) . The frequency, dose, and administration period of each inotropic were not different between groups A and C, except for the frequency of dopamine (group A: 43.5% versus group C: 80.0%; P < 0.01; Table II ). The mean doses of dopamine and dobutamine were 3.3 ± 1.4 µg/kg/min and 3.5 ± 1.3 µg/ kg/min, respectively.
In patients with high bilirubin, BP was controlled similarly between groups A and B, except for diastolic BP on admission. The heart rate decreased during the first 5 in-hospital days in groups A and B (Figure 1 ). However, there were significant differences in diuresis (1726 ± 418 versus 1458 ± 424 mL/day; P < 0.05), BW change (-3.1 ± 1.6 versus -2.1 ± 2.2 kg; P < 0.05), T-Bil (-0.74 ± 0.51 versus -0.04 ± 0.60 mg/dL; P < 0.01), and Cr (-0.29 ± 2.89 versus -0.01 ± 0.24 mg/dL; P < 0.01) between group A and group B (Table III, Figure 2 ). T-Bil levels at discharge when HF was adequately controlled were not different between groups A and B (0.76 ± 0.39 versus 0.82 ± 0.52; NS, Figure 2 ). On the other hand, in patients with low bilirubin, BP and HR were also controlled similarly between BP was controlled similarly between groups A and B or C and D, except for the data on admission. Group A had increased SBP (P = 0.04) and group C had increased SBP (P = 0.02) and DBP (P = 0.03) during the first 5 in-hospital days. There was no significant difference in HR between groups A and B or C and D. All groups had decreased HR during the first 5 in-hospital days (P < 0.01, respectively). BP indicates blood pressure; SBP, systolic blood pressure; DBP, diastolic blood pressure; and bil, bilirubin.
groups C and D, except for BP on admission (Figure 1 ). There were no significant differences in diuresis (1557 ± 329 versus 1507 ± 406; NS), BW change (-2.9 ± 1.7 versus -2.8 ± 1.5 kg; NS), T-Bil change (-0.01 ± 0.25 versus -0.08 ± 0.23 mg/ dL), or Cr change (0.02 ± 0.24 versus 0.47 ± 0.19 mg/dL; NS) between groups C and D (Table III, Figure 2 ). No clinical events indicating myocardial ischemia were seen during the observation period. In addition, there was no significant difference between patients with or without inotropics in the incidences of arrhythmia such as non- sustained ventricular tachycardia (NSVT: 5/39 versus 6/92; NS), sustained VT (1/39 versus 0/92; NS), atrial fibrillation (AF; 3/39 versus 5/92; NS), or paroxysmal supraventricular tachycardia (PSVT: 0/39 versus 3/92; NS). Subsequent introduction of inotropics: In patients who did not receive inotropics beginning the first in-hospital day, subsequent administration of inotropics due to unsatisfactory clinical improvement was significantly more frequent in group B than in group D (26 versus 4%; P < 0.01).
DISCUSSION
Recognition of hypoperfusion in HF:
Intravenous inotropic agents remain an important component of the therapeutic treatment of acute cardiac decompensation in chronic HF patients, however, meta-regression analysis has failed to show any benefit in terms of morbidity and mortality with their acute use; 11) leading to the global recommendation that they not be used as routine therapeutic tools. In the updated guideline of the European Society of Cardiology on the treatment of acute heart failure, their use is indicated only for patients in the presence of peripheral hypoperfusion with or without congestion refractory to diuretics and vasodilators at optimal doses. 5) However, apart from obvious cardiogenic shock with low BP, it is not always easy to recognize "hypoperfusion" or "low cardiac output" compared with the signs of "congestion". Several clinical signs such as cold extremities, general fatigue, impaired mentation, or decreased urination could be signs with which to detect "hypoperfusion", however, they are not specific and are often difficult to notice, especially without concomitant signs of congestion. Although a pulmonary artery catheter makes it easy to recognize the hemodynamics, it is not recommended for all patients due to its invasiveness and complications. 5) Adequate introduction of inotropic agents according to bilirubin levels: We have focused on the liver dysfunction concomitant with an acute exacerbation of HF, because its causative mechanism must be derived from the combination of congestion and low cardiac output 6, 7) which are often seen in severe HF patients. Several studies have shown so far that serum bilirubin is correlated with hemodynamic parameters such as right atrial pressure (RAP), 6, 7, 12) PAWP, 6) LVEF, 12) and CI. 6) Our previous study also demonstrated that serum T-Bil had the best correlations among liver function tests at the time of acute decompensation with simultaneously measured CVP (R = 0.42, P < 0.01), PAWP (R = 0.41, P < 0.01), and CI (R = -0.50, P < 0.01), respectively. 8) These findings led us to the assumption that increased serum bilirubin could be a noninvasive parameter which indicates the need for intravenous inotropics through the reflection of congestion and especially low cardiac output at the time of acute decompensation.
In patients with high bilirubin, immediate use of intravenous inotropics contributed to the abrupt compensation of deteriorated hemodynamics supported by significantly abundant diuresis, BW reduction, and decreased Cr and T-Bil. However, patients without inotropics demonstrated consistently high levels of T-Bil, which indicate unsatisfactory improvement from congestion and tissue hypoperfusion, which led to the subsequent administration of intravenous inotropics in 26% of patients. On the other hand, in patients with low bilirubin, intravenous inotropics were not necessarily indispensable, as ascertained by similar urine volume and BW reduction between patients with or without inotropics; and only 4% of patients required subsequent intravenous inotropics. Controversial aspects of inotropics use in HF management: The main point of the discussion on the pros and cons of using inotropics would be their adverse effects. Inotropics increase oxygen demand and calcium loading, leading to arrhythmia or myocardial ischemia during the administration period. 11) Ischemia could cause necrosis of hibernating myocardium which may result in deteriorated pump performance, possibly affecting the long-term prognosis. 13) It has been widely recognized, however, that these adverse effects are dose-dependent. 11, 14) In our study population, there were no ischemic events during the observation periods and no significant difference in the new onset of arrhythmia such as AF, PSVT, or VT between patients with or without inotropics. These findings might be the result of the low administered dose of inotropics (averaged dose of adrenergic agonists was approximately 3 µg/kg/min) in our study, which did not increase the HR and contributed to only a slight increase in BP during the administration period.
As many investigations caution against the routine use of intravenous inotropics in HF decompensation, we should restrict their administration to patients with low perfusion, who really require these drugs. Most guidelines recommend adequate introduction of inotropics with reference to low SBP which presumably reflects hypoperfusion; however, normal vital signs do not necessarily guarantee adequate systemic oxygen delivery. For example, some occult shock patients have global tissue hypoxia but otherwise have normal vital signs. 15) The present study demonstrated for the first time that increased levels of serum bilirubin coincident with HF decompensation despite preserved BP would be a hallmark to select noninvasively patients who need intravenous inotropics. Limitations of the study: The study was carried out inside a single institute in both a retrospective and nonrandomized fashion. In addition, ideally there should be no significant difference in clinical severity among the groups. This is impossible, however, since the serum bilirubin levels are determined by the severity of the hemodynamics. This is one limitation of this study that needs to be acknowledged.
It is conceivable that patients with low blood pressure including a cardio-genic shock state would derive a benefit from using inotropics, as interpretable from the HF guidelines. 3) Conversely, patients with preserved SBP tend to have different reasons for high bilirubin other than deteriorated hemodynamics (data not shown), which might affect the results of this study. Since the main purpose of this investigation was to introduce the proper use of inotropics in HF patients, we limited ourselves to patients demonstrating a systolic blood pressure of 90 to 120 mmHg upon admission to hospital.
